Refine
Has Fulltext
- yes (9)
Is part of the Bibliography
- yes (9)
Document Type
- Journal article (9)
Language
- English (9)
Keywords
- B cells (4)
- MS (3)
- multiple sclerosis (3)
- relapse (3)
- EAE (2)
- ELISPOT (2)
- expression (2)
- predictive value (2)
- Alemtuzumab (1)
- CD52 (1)
- CNS (1)
- FTY720 (1)
- PCDHGC3 (1)
- TLO (1)
- WNT signaling (1)
- antibodies (1)
- astrocytoma (1)
- autoimmunity (1)
- blood coagulation (1)
- brain (1)
- cortical pathology (1)
- dendric cells (1)
- disability (1)
- disease (1)
- factor XII (1)
- fingolimod (1)
- glioblastoma multiforme (1)
- glioma (1)
- hematopoietic (1)
- lesions (1)
- mRNA (1)
- meninges (1)
- mouse (1)
- myeloid (1)
- natural history (1)
- neuroimmunology (1)
- neuroinflammation (1)
- progenitor (1)
- protein (1)
- recurrence (1)
- trial (1)
Institute
- Institut für Anatomie und Zellbiologie (9) (remove)
B cell aggregates in the central nervous system (CNS) have been associated with rapid disease progression in patients with multiple sclerosis (MS). Here we demonstrate a key role of carcinoembryogenic antigen-related cell adhesion molecule1 (CEACAM1) in B cell aggregate formation in MS patients and a B cell-dependent mouse model of MS. CEACAM1 expression was increased on peripheral blood B cells and CEACAM1\(^+\) B cells were present in brain infiltrates of MS patients. Administration of the anti-CEACAM1 antibody T84.1 was efficient in blocking aggregation of B cells derived from MS patients. Along these lines, application of the monoclonal anti-CEACAM1 antibody mCC1 was able to inhibit CNS B cell aggregate formation and significantly attenuated established MS-like disease in mice in the absence of any adverse effects. CEACAM1 was co-expressed with the regulator molecule T cell immunoglobulin and mucin domain −3 (TIM-3) on B cells, a novel molecule that has recently been described to induce anergy in T cells. Interestingly, elevated coexpression on B cells coincided with an autoreactive T helper cell phenotype in MS patients. Overall, these data identify CEACAM1 as a clinically highly interesting target in MS pathogenesis and open new therapeutic avenues for the treatment of the disease.